Criteria for a clinically informative serum biomarker in acute ischaemic stroke: A review of S100B

Cerebrovascular Diseases

Volumn 27, Issue 3, 2009, Pages 295-302

  Dassan, Pooja ^a   Keir, Geoffrey ^a   Brown, Martin M ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Acute ischaemic stroke; Biomarker; S100B protein

Indexed keywords

BIOLOGICAL MARKER; FIBRINOLYTIC AGENT; PROTEIN S100B; TISSUE PLASMINOGEN ACTIVATOR;

BLOOD CLOT LYSIS; BRAIN DAMAGE; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; DISEASE MARKER; HEART INFARCTION SIZE; HIGH RISK PATIENT; HUMAN; NEUROLOGICAL COMPLICATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; STROKE PATIENT;

BIOLOGICAL MARKERS; BRAIN ISCHEMIA; HUMANS; KINETICS; NERVE GROWTH FACTORS; PREDICTIVE VALUE OF TESTS; RECOVERY OF FUNCTION; S100 PROTEINS; SEVERITY OF ILLNESS INDEX; STROKE; TREATMENT OUTCOME; UP-REGULATION;

EID: 59449099138     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000199468     Document Type: Review

References (40)

1. Biomarkers Definitions Working Group: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89.
2. Kidwell CS, Chalela JA, Saver JL, et al: Comparison of MRI and CT for detection of acute intracerebral hemorrhage. JAMA 2004;292:1823-1830.
3. Jager HR: Diagnosis of stroke with advanced CT and MR imaging. Br Med Bull 2000;56:318-333.
4. Wardlaw JM, Lewis SC, Dennis MS, et al: Is visible infarction on computed tomography associated with an adverse prognosis in acute ischemic stroke? Stroke 1998;29:1315-1319.
5. Davis SM, Donnan GA, Butcher KS, Parsons M: Selection of thrombolytic therapy beyond 3 h using magnetic resonance imaging. Curr Opin Neurol 2005;18:47-52.
6. Harbison J, Massey A, Barnett L, et al: Rapid ambulance protocol for acute stroke. Lancet 1999;353:1935.
7. Harbison J, Hossain O, Jenkinson D, et al: Diagnostic accuracy of stroke referrals from primary care, emergency room physicians, and ambulance staff using the face arm speech test. Stroke 2003;34:71-76.
8. Scott PA, Silbergleit R: Misdiagnosis of stroke in tissue plasminogen activator-treated patients: characteristics and outcomes. Ann Emerg Med 2003;42:611-618.
9. Hemmen TM, Meyer BC, Hayes KA, et al: Identification of 'stroke-mimics' among 411 code strokes at the UCSD Stroke Center from September 1998 to March 2001. Stroke 2002;33:385.
10. Davalos A, Toni D, Iweins F, et al: Neurological deterioration in acute ischemic stroke - potential predictors and associated factors in the European Cooperative Acute Stroke Study (ECASS) I. Stroke 1999;30:2631-2636.
11. Toni D, Fiorelli M, Gentile M, et al: Progressing neurological deficit secondary to acute ischemic stroke - a study on predictability, pathogenesis, and prognosis. Arch Neurol 1995;52:670-675.
12. Vahedi K, Hofmeijer J, Juettler E, et al: Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol 2007;6:215-222.
13. Hjort N, Wu O, Ashkanian M, et al: MRI detection of early blood-brain barrier disruption - parenchymal enhancement predicts focal hemorrhagic transformation after thrombolysis. Stroke 2008;39:1025-1028.
14. Moore BW: A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 1965;19:739-744.
15. Donato R: S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001;33:637-668.
16. Steiner J, Bernstein HG, Bielau H, Berndt A, Brisch R, Mawrin C, Keilhoff G, Bogerts B: Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neurosci 2007;8:2.
17. Kapural M, Krizanac-Bengez L, Barnett G, et al: Serum S-100 beta as a possible marker of blood-brain barrier disruption. Brain Res 2002;940:102-104.
18. Persson L, Hardemark HG, Gustafsson J, et al: S-100 protein and neuron-specific enolase in cerebrospinal-fluid and serum - markers of cell-damage in human central-nervous-system. Stroke 1987;18:911-918.
19. Abraha HD, Butterworth RJ, Bath PMW, et al: Serum S-100 protein, relationship to clinical outcome in acute stroke. Ann Clin Biochem 1997;34:366-370.
20. Fassbender K, Schmidt R, Schreiner A, et al: Leakage of brain-originated proteins in peripheral blood: temporal profile and diagnostic value in early ischemic stroke. J Neurol Sci 1997;148:101-105.
21. Buttner T, Weyers S, Postert T, et al: S-100 protein: serum marker of focal brain damage after ischemic territorial MCA infarction. Stroke 1997;28:1961-1965.
22. Missler U, Wiesmann M, Friedrich C, et al: S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke 1997;28:1956-1960.
23. Elting JW, de Jager AEJ, Teelken AW, et al: Comparison of serum S-100 protein levels following stroke and traumatic brain injury. J Neurol Sci 2000;181:104-110.
24. Herrmann M, Vos P, Wunderlich MT, et al: Release of glial tissue-specific proteins after acute stroke - a comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke 2000;31:2670-2677.
25. Wunderlich MT, Wallesch CW, Goertler M: Release of neurobiochemical markers of brain damage is related to the neurovascular status on admission and the site of arterial occlusion in acute ischemic stroke. J Neurol Sci 2004;227:49-53.
26. Foerch C, Singer OC, Neumann-Haefelin T, et al: Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction. Arch Neurol 2005;62:1130-1134.
27. Jauch EC, Lindsell C, Broderick J, et al: Association of serial biochemical markers with acute ischemic stroke - the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study. Stroke 2006;37:2508-2513.
28. Foerch C, de Rochemont RD, Singer O, et al: S100B as a surrogate marker for successful clot lysis in hyperacute middle cerebral artery occlusion. J Neurol Neurosurg Psychiatry 2003;74:322-325.
29. Foerch C, Otto B, Singer OC, et al: Serum S100B predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion. Stroke 2004;35:2160-2164.
30. Foerch C, Wunderlich MT, Dvorak F, et al: Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke 2007;38:2491-2495.
31. Raabe A, Menon DK, Gupta S, et al: Jugular venous and arterial concentrations of serum S-100B protein in patients with severe head injury: a pilot study. J Neurol Neurosurg Psychiatry 1998;65:930-932.
32. Ishiguro Y, Kato K, Ito T, Nagaya M: Determination of 3 enolase isozymes and S-100 protein in various tumors in children. Cancer Res 1983;43:6080-6084.
33. Reynolds MA, Kirchick HJ, Dahlen JR, et al: Early biomarkers of stroke. Clin Chem 2003;49:1733-1739.
34. Lynch JR, Blessing R, White WD, et al: Novel diagnostic test for acute stroke. Stroke 2004;35:57-63.
35. Laskowitz DT, Blessing R, Floyd J, White WD, Lynch JR: Panel of biomarkers predicts stroke. Ann NY Acad Sci 2005;1053:30.
36. Pulsinelli WA, Brierley JB, Plum F: Temporal profile of neuronal damage in a model of transient forebrain ischemia. Ann Neurol 1982;11:491-498.
37. Oppenheim C, Samson Y, Manai R, et al: Prediction of malignant middle cerebral artery infarction by diffusion-weighted imaging. Stroke 2000;31:2175-2181.
38. Mayer TE, Schulte-Altedorneburg G, et al: Serial CT and MRI of ischaemic cerebral infarcts: frequency and clinical impact of haemorrhagic transformation. Neuroradiology 2000;42:233-239.
39. Weimar C, Ziegler A, Konig IR, et al: Predicting functional outcome and survival after acute ischemic stroke. J Neurol 2002;249:888-895.
40. Counsell C, Dennis M, McDowall M: Predicting functional outcome in acute stroke: comparison of a simple six variable model with other predictive systems and informal clinical prediction. J Neurol Neurosurg Psychiatry 2004;75:401-405.